We know gout is among the many comorbidities that increase the risk of cardiovascular disease (CVD). In 2018, the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial concluded that febuxostat was non-inferior to allopurinol. BUT, two of the secondary endpoints were very concerning. Febuxostat was inferior to allopurinol in terms of cardiovascular death and all-cause mortality. Many clinicians were left wondering whether febuxostat was cardiotoxic …. or conversely, perhaps allopurinol was cardioprotective. Will another cardiovascular outcome trial provide greater clarity to guide clinical practice?
Guest Authors: Sophia Dietrich, PharmD and Michael W. Nagy, PharmD, BCACP
Guest Panelist: Dawn Fuke, PharmD, BCPS
Music by Good Talk
Is Combination Therapy Superior to Monotherapy for Painful Diabetic Peripheral Neuropathy?
How VITAL is Vitamin D in Preventing Statin Associated Muscle Symptoms (SAMS)?
Under Pressure: Measuring and Managing Hypertension
Top Ten Things Every Clinician Should Know About Payment for Pharmacists’ Patient Care Services
Complex Patient Case 2 - Managing Adverse Effects
Preventing Autoimmune Disease: Can Supplements Get the Job Done?
Top Ten Things Every Clinician Should Know About Treating Obesity
Managing RAAS-Inhibitor-Associated Hyperkalemia in Patients with CKD – A Balancing Act
Complex Patient Case - Women’s Health + Contraception
Top Ten Podcasts Every Ambulatory Care Clinician Should Know About
The Generic Levothyroxine Conundrum
Is Icosapent Ethyl a QALY-ty Investment?
Level Up! An Abstinence Game for Smoking Cessation
Breaking the SABA-only Rescue Habit: Two Drugs Are Better Than One
Are You Sure? Tolerance of Uncertainty and the Risk of Stress-Related Harm
Top Ten Things Every Clinician Should Know About the 2022 Heart Failure Guidelines
SAGE Wisdom: Analysis of a Self-Administered Gerocognitive Test
Educating Patients and Prescribers About Deprescribing to Reduce Medication Burden May Not Be Enough
Treating mild hypertension during pregnancy: Time for a new CHAPter!
Finally! Something FDA-Approvable for Non-alcoholic Steatohepatitis (NASH)?
Create your
podcast in
minutes
It is Free
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive